Meeting
2023 ASCO Annual Meeting
A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
Authors
Mansoor Raza Mirza
NSGO-CTU & Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Mansoor Raza Mirza , Klaus Pietzner , Els Van Nieuwenhuysen , Christian Marth , Ingrid Boere , Kristina Lindemann , Josefin Fernebro , Sakari Hietanen , Birute Brasiuniene , Kirsten Pors , Signe Gybel Frederiksen , Ulrikke Ji Mee Willerslev , Elena Ioana Braicu , Kristine Madsen , Flora Zagouri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04742075
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5615)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5615
Abstract #
TPS5615
Poster Bd #
308b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.
First Author: Angelina Tjokrowidjaja
Poster
2023 ASCO Annual Meeting
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.
First Author: Genevieve MacAulay Vacheresse
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim